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Abstract
Ceramide is a sphingolipid second messenger that is
involved in apoptosis and other cellular responses to
stress.

Ceramide generation occurs primarily by two

methods: hydrolysis of sphingomyelin by sphingomyelinases or
by de novo synthesis, which is initiated on the surface of
the endoplasmic reticulum by serine palmitoyltransferase
(SPT).

The de novo synthesis of ceramide is activated in

response to' retinoic acid, chemotherapeutic agents like
etoposide or daunorubicin, and TNF- . We have shown
previously that SPT is activated in response to chemotherapy
~

and governs de novo ceramide production. To determine
factors that regulate SPT and the de novo pathway we have
investigated this pathway in cells over-expressing Bcl-2.
Bcl-2 is a 26-kDa integral membrane oncoprotein that is
capable of suppressing apoptosis. It prevents many of the
morphological and biochemical changes observed in apoptosis.
It was shown that Bcl-2 interrupts apoptosis by different
mechanisms such as forming heterodimers with Bax, affecting
Ca+ 2 flux, or preventing the release from the mitochondria of
apoptotic activators like cytochrome c and AIF. We herein
demonstrate a caspase-dependent induction of de novo
ceramide in etoposide-induced apoptosis and its inhibition
by Bcl-2.
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Introduction
Sphingo1ipids
Sphingolipids are a diverse group of compounds that
differ from glycerolipids in having a sphingoid base
instead of glycerol as the cornman structural component
(figure 1). Structurally, the most basic sphingolipids are

the sphingoid or long-chain bases (lcb) sphinganine and
sphingosine. These can be acylated through their amino
group to produce dihydrocerarnide or ceramide, respectively.
Fina~ly,

the complex sphingolipids are formed by the

addition of polar head groups to ceramide.
The key sites on sphingolipid molecules are located on
carbons 1-5 of the sphingoid backbone. These functional
groups confer on sphingolipids their important biological
functions and specificity. C-1 and C-3 are the locations of
hydroxyl groups and the C-3 hydroxyl group serves as the
site for polar headgroup addition. C-2 is the site of the
amino group through which the fatty acid is attached, and
C-4/C-5 is the location of the trans double bond, which
confers specificity_ Importantly, dihydroceramide which
differs from ceramide only in that it is fully saturated at
C-4/C-5 is without signaling function in all the systems
tested (£igure 1) .
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Ceramide generation

Ceramide can be generated from three sources. One of
~

these is by sphingomyelin hydrolysis, which was the first
route identified for generation of a signaling pool of
ceramide. A second source of ceramide generation is through
the de novo pathway which has long been known to provide
substrates for complex sphingolipids biosynthesis and in
recent years has been observed to supply its own signaling
pool of ceramide. The third source of ceramide is the
salvage pathway in which sphingosine from catabolic
processes is reacylated to form ceramide (reference 5).

Ceramide fate
After ceramide is generated from the de novo pathway,
it can be subject to a number of metabolic modifications.
Some of the simplest of these include phosphorylation of
the C-1 hydroxyl group to produce ceramide-l-phosphate or,
alternatively, acylation at the same position to produce 1O-acylceramide. Both of these are metabolic routes that
have not been shown to be quantitatively significant.
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Other more quantitatively important modifications of the 1OH group include the addition of a phosphorylcholine
headgroup to yield sphingomyelin or the addition of glucose
to yield glucosylceramide. A final important metabolic
route is the catabolism of ceramide by ceramidase to from a
free fatty acid and sphingoid base (reference 6).

De novo biosynthesis

(Figure 2)

In our laboratory we focused our attention on the de
novo pathway with special interest in its

regulator~

and

modulators. The enzymes of the de novo pathway are oriented
on the cytosolic face of the endoplasmic reticulum (ER) as
shown by Mandon et al (reference 7) in 1992. The pathway
starts with the condensation of serine and palmitoyl eoA
resulting in an 18 carbon sphingoid backbone. This initial
reaction is mediated by serine palmitoyl transferase (SPT),
which will be discussed in more detail later. The product
of this condensation reaction is 3-ketosphinganine, which
undergoes reduction by ketosphinganine reductase to yield
sphinganine (dihydrosphingosine) which is, in turn,
acylated by ceramide synthase (dihydroceramide synthase) to
give dihydroceramide. Finally, the double bond is added by
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dihydroceramide desaturase to yield ceramide. So the de
novo biosynthesis can be summarized in three stages: the
synthesis of a long-chain base, the formation of ceramide
by N-acylation, and finally, the transport of ceramide to
the Golgi for headgroup addition.

Why is the de novo pathway important?
The short answer to the above question is because it
is an important source of ceramide. Ceramide is implicated
in different cell functions like proliferation, cell cycle
regulation, senescence, and apoptosis. For all these
reasons de novo biosynthesis is vital for cellular
functions in signaling. It is also an essential pathway
since sphingoid bases are required for cell growth although
it's unclear if

~his

is related to a signaling or

structural integrity event. Finally, because the de novo
pathway is involved in generating signaling molecules that
program cellular events, it is implied that the pathway has
tightly controlled regulatory mechanisms.

4

Apoptosis
A- Chemotherapy induced apoptosis (reference 9 for more
review)
De novo ceramide synthesis can induce apoptosis in response
to different chemotherapeutic agents. Etoposide can
activate apoptosis via de novo ceramide synthesis in Molt-4
human T-Ieukemia cells (reference 8). This was through SPT
activation through post-translational modulation since SPT
mRNA levels did not change. Also, daunorubicin in the P388
murine leukemia cell line and U937 human monoblastic
leukemia cells induced the de novo pathway and programmed
cell death by activating dihydrocerarnide synthase
(reference 10). This conduct was not limited to
hematological cancers but also included many of the solid
tumors cell lines; camptothecin in 4Bl
mouse fibroblasts,

(also called L929)

taxol in MCF-7 breast cancer cells, and

gerncitabine in A549 lung cancer cell line (references 1113) .
It should be noted that induction of de novo ceramide does
not obligate an apoptotic response. Akao et al

(reference

14) demonstrated this when they treated LNCaP prostate
cancer cells with camptothecin (CPT-II). Here the cell
death caused by CPT-II was not because of increased de novo
ceramide generation. De novo ceramide is synergistic to

5

radiation therapy as is the case when treating LNCaP cells
with 12-0-tetradecanoylphorbol acetate (TPA)
Neither agent induced apoptosis alone

or radiation.

(reference 15).

The cerarnide-induced apoptosis is gaining more attention
because of new challenges to old notions regarding how
chemotherapy induces programmed cell death. It was shown in
murine mammary cell lines that cell cycle arrest and
apoptosis caused by taxol are not synonymous processes
(reference 12). Similar doubts were also cast on
daunorubicin-induced apoptosis mechanisms because it was
shown that apoptosis could be induced under conditions
where no free drug is available intra-cellularly (re';ference
16) .

B-Fatty acids induced apoptosis
Research has shown that de novo synthesis induced apoptosis
can be activated by applying fatty acids like palmitate or
stearate directly or by creating conditions that increase
their availability to the de novo pathway by means of
inhibiting beta-oxidation with agents like etomoxir that
inhibits carnitine palmitoyltransferase (CPT-I)

(reference

17). This data was further substantiated using reverse
methodology by Shimabukuro et al

(reference 11). They were

able to inhibit apoptosis by inhibiting fatty acyl-CoA
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,

synthase or enhancing free fatty acids beta-oxidation using
triacsin C or troglitazone, respectively.
C-Retinoic acid (RAJ induced apoptosis
PCC7 teratocarcinoma cell line responds to all-trans RA by
differentiation and apoptosis. In this system, retinoic
acid activated SPT leading to an increase in de novo
ceramide generation (reference 19). Treating the GH4C1 rat
pituitary cell line with all-trans RA also induced de novo
ceramide but through increasing sphingosine N-acylation
(reference 20). Other RA derivatives like the synthetic RA,
N- (4-Hydroxyphenyl) retinamide (4-HPR) produce a similar
response in CHL90 neuroblastoma cells by activating both
SPT and dihydroceramide synthase (reference 21).
D- Cytokines induced apoptosis
TNF-alpha induced cell death alone or with cycloheximide
aid in MCF-7 or bovine cerebral endothelial cell line
(BCECs) cells respectively. In both cases this induced
apoptosis was through activating the de novo synthesis
pathway (references 74 and 75). In MCF-7 cells
sphingomyelin hydrolysis was also activated.
E- BcR cross linking in B-cells
In the Ramos cell line (Epstein-Barr negative Burkitt's
lymphoma cells) BcR cross-linking induced cell death via
activating de novo ceramide generation (reference 22)
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F- Cannabinoid-mediated apoptosis
Both tetrahydrocannabinol (THC) and the CB2 selective
-

agonist JWH-133 increased de novo ceramide synthesis
causing cell death in glioma cells (references 24 and 25) .
It is apparent from all of the data collected that
different stress agents can induce de novo ·ceramide in a
variety of systems and the consequence of this induction is
often apoptosis.

The nervous system
It is estimated that about 20-80% of neurons die during
brain development. This is due to the neurotrophic

s~rategy

where excess neurons are made to maximize enervation
capacity, then, those without synaptic connections expire
(reference 19). Ceramide from both de novo and
sphingomyelin hydrolysis has been implicated in nervous
system apoptosis. De novo biosynthesis is also involved in
neuronal differentiation, which was shown by retinoic acid
experiments in PCC7-Mz1 teratocarcinoma or Neuro2a
neuroblastoma cell lines (references 19 and 26). There is
mounting evidence exhibiting clear involvement of de novo
ceramide synthesis in nervous system pathology. This
includes a wide range of diseases like neurodegenerative
etiology. This is the case of Batten's disease where
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photoreceptors die by programmed cell death (reference 27).
It was found by Rylova et al that the gene responsible for
the disease, CLN3 is a negative regulator of de novo
ceramide biosynthesis

(reference 28). De novo ceramide in

the nervous system is an important factor in other
pathological processes like the inflammatory process in
response to cytokines like TNF-alpha (reference 74) and
cannabinoid mediated effects through their CBl or CB2
receptors

(reference 24). More interesting are the new

reports identifying 8PT mutations as the culprit in
hereditary sensory neuropathy type 1 (references 29 and
30). This is considered the first pathology of sphingolipid
metabolism that does not involve a lipid storage disease.

The immune system

De novo ceramide is responsible for activated induced cell
death (AICD)

in B-cells. This process is believed to

control B-cell populations and functions to protect the
body from autoimmune diseases

(reference 22). The CB2

receptor is a cannabinoid receptor that is restricted to
brain tumors and immune system cells. The CB2 selective
agonist JWH131 inhibited glioma cell growth by activating
de novo ceramide. However there may be also a down side for
ceramide activation by inhibiting the immune system
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response to malignant cells due to the presence of CB2
receptors

(reference 25).

Epiderma1 barrier integrity (references 31-33)
Holleran et ale demonstrated that by disrupting the
epidermal barrier using chemical, physical or pathological
methodology, the biosynthesis pathway for sphingolipids is
activated via inducing SPT activity. The epidermal recovery
was sequential with an increase in cholesterol first,
followed by sphingolipids later. Farrell et ale was able to
show that UVB irradiation will increase SPT activity in
keratinocytes by up regulating the LCB2

(2.3KB) mRNA

(reference 33).

other functions and patho1ogies
De novo biosynthesis is implicated indirectly in a wide
range of non-nervous system diseases. This is very clear
from the occurrence of the harmful effects of fumonisin B
in humans and animals, which are, associated with an
increase in the sphingoid base levels in urine and plasma
samples

(references 34 and 35). These diseases include

equine leukoencephalopathy, porcine pulmonary edema, and
murine hepatotoxicity. In humans fumonisin B is implicated

10

in endemic esophageal cancer in South Africa (reference 34)
and endemic nephropathy in Croatia and other parts of
Eastern Europe (reference 36). The de novo pathway is also
being implicated in atherosclerosis, obesity and diabetes
(references 37-39 and 18). Other functions of de novo
ceramide biosynthesis are cell cycle progression via
dephosphorylating Rb protein (reference 40),
serine/arginine-rich (SR) protein phosphorylation which
regulates alternative splicing (references 13 and 41), and
modulating drug resistance (reference 42).

De novo synthesis modulators
Inhibitors
1) SPT inhibitors: myriocin, beta-chIaro-alanine, betafluoro-alanine, and L-cycloserine. Sphingoid bases or
their homologues are also important inhibitors for de
novo sphingolipid biosynthesis, and may play an
important role in the endogenous regulation of SPT
activity and sphingolipid biosynthesis. The sphingoid
base inhibition effect is dose-and time dependent, SPT
specific, and stereo specific (references 43-45).
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The

full-length wild type leptin receptor (OB-Rb) also
inhibits SPT activity (reference 39).
2)

Dihydroceramide synthase (N-acylsphingosine
transferase)

inhibitors:

Fumonisin B compounds are the most widely known and
they inhibit dihydroceramide synthase by competitive
inhibition with its substrates. As shown in (figure 3)
(reference 35) there is a great resemblance of
fumonisin B to the sphingoid bases. Fumonisin B can
inhibit both the salvage pathway as well as the de novo
by blocking N-acylation of sphingosine and sphinganine.
~

3)

Indirect inhibition of de novo ceramide can be
achieved through manipulating fatty acid oxidation or
by regulating enzymes that degrade the de novo
synthesis metabolites. This regulation occurs with 1methylthiodihydroceramide (l-MSDH-cer) which inhibits
de novo synthesis by activating sphinganine kinase,
leading to degradation of sphinganine (reference 46).

Activators
1) SPT activators include; chemotherapeutic agents like
etoposide, all-trans retinoic acid or synthetic
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retinoid like 4-HPR, UV irradiation, and fatty acids
(references 8, 18-21, and 33) .
2)

Dihydroceramide synthase activators: daunorubicin, 4HPR, and TPA (references 10, 21, 15, and 47).

Paradox and comp1exity in studying ceramide
The study of ceramide is at times complicated by
contradictory results. These difficulties are due to
specificity in sphingolipid functions. This specificity can
be system directed, agent specific, or related to the cell
status like maturity or differentiation. This applies to
ceramide generated from sphingomyelin or de novo pathways.
Since our interest here is de novo we will use examples
related to the de novo pathway. First, LNCaP prostate
cancer cells are sensitive to TPA in the confluent status
but resistant in the plateau phase (references 47 and 15).
The second example is that mature Ramos B-Iymphoma cells
respond to BcR cross-linking differently from immature
WEH231 murine B-Iymphoma cell line (references 22 and 23).
Third, the PCC7 teratocarcinoma response to all-trans
retinoic acid is dependent on differentiation status
(reference 19). Fourth, agent specificity: while etoposide
induced de novo via SPT activation in Molt-4 human Tleukemia cell line, other agents like GW 1843 (reference
13

50)

induced a sphingomyelin source of ceramide. Fifth, is

dose and time differences; this is evident in the case of
daunorubicin and the U937 human leukemia cell line
(references 10 and 16). Bose et ale was able to induce de
novo ceramide by activating dihydroceramide synthase
(reference 10) while Jaffrezou showed neutral
sphingomyelinase activation (reference 16). It should be
noted that Bose et ale applied 10 micro molar daunorubicin
for 12 hours and Jaffrezou used only 1 micro molar for 4
hours.

Bc1-2 Oncogene
Bcl-2 was first identified at the chromosomal
breakpoint of t

(14; 18)

in human B-cell lymphomas. This

translocation brings the Bcl-2 gene under the control of
the actively transcribed 19 gene on chromosome 14. The Bcl2 family now includes pro-apoptotic proteins like BAX, BAD,
and BID, as well as anti-apoptotic members like Bcl-2 and
Bel-XL (reference 51). The anti-apoptotic members are found
in the mitochondrial, endoplasmic reticulum and nuclear
membranes, while the pro-apoptotic are located in the
cytosol or cytoskeleton. All the anti-apoptotic members are
composed of four Bcl-2 homology (BH) domains, BH1-BH4, with
the carboxy-terminal the hydrophobic domain that anchors
them to the membranes

(reference 52). The various methods
14

used to execute their anti- or pro-apoptotic functions
include: channel forming,

homo- or hetero-dimerization, or

binding to proteins that are involved in programmed cell
death

(reference 53). In the case of Bcl-2 it prevents

cytochrome c release and inhibits poly (ADP-ribose)
polymerase

(PARP) protease activation (reference 54 and

55). Bcl-2 was also found to interrupt downstream the
ceramide pathway in apoptosis without interfering with its
generation (references 56-58).

Serine Palmitoyltransferase
The 8PT enzyme is the rate-limiting enzyme that catalyzes
the first step in sphingolipid biosynthesis. Most of SPT
activity is localized to the microsomal fraction

(reference

61). SPT enzyme belongs to a subfamily of the pyridoxa15'phosphate utilizing enzymes. This subfamily is called the
alpha-oxoamine synthases, which catalyze the transfer of
the acyl group from an acyl-CoA to the alpha-carbon of an
amino acid.
In mammalian cells the SPT enzyme consists of two subunits,
LeB1 and LCB2, with. stoichiometry of 1:1

(reference 62).

Both LeB1 and.LCB2 'subunits are required for SPT activity
(references 63 and 64). However, Weiss and Stoffel
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demonstrated that in human embryonic kidney cells

(HEK 293)

the over expression of LCB2 increases SPT activity
(reference 65). According to Hanada this might be due to
forming complexes between the endogenous LCB1 and the over
expressed LCB2

(reference 63).

In yeast SPT is necessary

for growth (references 66-68). Activity also requires both
LCBl and LCB2 subunits

(references 68-70).

isolated an 80-amino acid protein (Tsc3p)
of the SPT complex in yeast

Dunn et ale
that may be part

(reference 71).

In eukaryotes the SPT subunits are hydrophobic, membraneassociated proteins with potential transmembrane helices,
while in bacteria the SPT enzyme is a water-soluble
homodimeric protein (reference 72). Although it was first
identified in the late sixties,

SPT has been gaining

renewed interest due to its implication signaling and human
disease. Nicholson et ale

(reference 30)

observed mutations

in SPT of patients with hereditary sensory neuropathy type
I and postulated that these cause an increase in SPT
activity leading to the production of more de novo
ceramide.

Predicting this will lead to neural degeneration

and more apoptosis. However,
ale

(reference 73)

the

r~~ent

paper by Dunn et

showed that similar mutations in yeast

have inhibitory effect on SPT. This discovery will
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represent more challenges to researchers and further the
impetus for studying SPT.
Others and we have demonstrated that cellular stress agents
can activate SPT and lead to upregulation of de novo
ceramide and apoptotic responses. We also know that these
agents due not interact directly with SPT. Therefore, we
were interested in identifying endogenous upstream
regulators of SPT in the de novo pathway.
One lead came from earlier data demonstrating the integral
relationship between ceramide, caspases, and bcl-2
(reference 58). This work demonstrated that although bcl-2
prevents apoptosis and the activation of executioner
caspases, it does not interfere with ceramide production
from agents that turn on sphingomyelinase activation. As de
novo cerarnide production differs spatially in the cell from
that produced by sphingomyelinases, we set out to determine
if bcl-2 was capable of regulating de novo ceramide
production and if caspases were involved in this process.
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Materia1s and Methods
Materials: ceramide standards were purchased from
Avanti polar lipids.

[Gamma- 32 P]ATP (3000 Ci/mmol) and [9,

10_3 H J palmitic acid (43 Ci/mmol] were purchased from NEN.
Etoposide was purchased from sigma, and z-VAD.fmk peptide
from Calbiochem. GW 554869a was obtained from Dr. Yusuf
Hannun's lab.
Cell culture: Molt-4 T-leukemia cells from Zhang et al
were used for experiments

(reference 57). These cells had

been transfected with pMEP4 vector with and

withou~

full- length murine bcl-2. Cells were maintained at 37°C
and 5% C02 in RPMI medium with 10% fetal calf serum (FeS).

Ceramide mass measurements: Molt-4 cells were seeded
at 5x10 5 /ml in a 6-well plate (3mls/well). After the desired
treatment, ceramide mass was determined using the
diglyceride kinase assay (DGK) as
5x10 5 cells

(reference76). In summary

(equals 1 ml and 2 mls left for lipid phosphate

determination) were used for the DGK assay. These cells
were lysed in a mixture of chloroform and methanol

(1:2)

and lipids were extracted as prescribed by the Bligh and
Dyer method (reference 77) then solubilized in mixed
micelles for 30 minutes at 37°C. Three _9 of membranes from
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E.coli overexpressing DGK followed by the addition of three
pCi of [gamrna- 32 p] ATP in the presence of 1mM carrier ATP

and kept at room temperature. Thirty minutes later the
reaction was quenched with chloroform/methanol (1:2) and
the lipids extracted again based on the Bligh and Dyer
method. The chloroform was evaporated and the lipid pellet
was suspended in 40

I

of chloroform/ methanol

(4:1) and

resolved on TLC plates. The solvent system used was
chloroform/acetone/methanol/acetic acid/water (10:4:3:2:1).
After autoradiography, the ceramide location was identified
by iodine-staining of a ceramide standard and radioactivity
was quantified by liquid scintillation spectrometry.
Ceramide mass was quantified based on the standard curve
and normalized to lipid phosphate.
Lipid phosphate determination: Lipids extracted from

10 6 Molt-4 cells were concentrated to remove the chloroform.
Then the lipid pellets were incubated at 180°C overnight in
0.6 ml of 10 N H2S04/70%HCI04/H20 (9:1:40). Then,

0.6 ml of

H20, 0.5 ml of 0.9% ammonium molybdate, and 0.2 ml of 9.0%
freshly made ascorbic acid were added and incubated for 30
minutes at 45°C.

Inorganic phosphate was detected by

absorbance at 820 nm and quantified based upon a standard
curve of K2HP04.
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Radiolabeling of cells: Molt-4 cells were seeded at

5xl0 5 /ml (3mls/well in a 6-well plate). 1 _Ci/ml of

[3 H]

palmitate was added with 10 micromolar of etoposide at the
same time. At the desired time point cells were lysed in a
mixture of chloroform and methanol (1:2) and lipids were
extracted according to the Bligh and Dyer method. The
chloroform phase was evaporated in a speed vacuum device
and the lipid pellets were suspended in 40

I of

chloroform/methanol (4:1) and resolved on TLC plate. The
solvent system used was chloroform/methanol/2N NH 4 0H
(40:10:1). After chromatography, the ceramide standard was
identified using iodine vapors. Then, TLC plates were
sprayed with enhancer, and radioactivity was visualized by
autoradiography after 48-72 hours at -80°C. The radioactive
spots corresponding to the ceramide standard were scraped
and quantified by liquid scintillation spectrometry.
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Results and discussion
Our investigations were predicted on data we had previously
established showing that the topoisomerase inhibitor and
chemotherapy agent etoposide caused a several-fold
elevation of ceramide mass in Molt-4 cells (Figure 10) .
Importantly, it was also demonstrated that the
dihydroceramide synthase inhibitor, fumonisin,

inhibited

this increase in ceramide suggesting its generation from
the de novo pathway (reference 8). The involvement of de
novo ceramide synthesis was further substantiated by
showing that etoposide indirectly activated the ratelimiting enzyme in the pathway, serine palmitoyltransferase
(reference 8).
As a starting point in looking for upstream regulators of
de novo ceramide production and for reasons we stated at
the conclusion of the introductory section, we proceeded to
utilize Molt-4 cells transfected with a control vector or
vector containing the murine bcl-2 oncogene. Overexpression
of murine bcl-2 predominantly in a heavy membrane fraction
in these cells had earlier been confirmed (reference 57).
Upon treatment of both cell lines with etoposide over a 12hour time course, we observed near total abatement of the
ceramide response in the bcl-2 over-expressing cells
compared to the vector control cells (figure 4) .
21

Importantly, ceramide mass was not diminished by an
inhibitor of the neutral sphingomyelinases implicated in
ceramide generation in apoptotic signaling. A Glaxo
Wellcome (G.W) compound inhibits this enzyme and TNFsignaling responses (reference 79). It was without effect
in our cells (figure 6) providing further support that
etoposide-induced ceramide is from the de novo pathway.
We also investigated the impact of bcl-2 on ceramide
generation as assessed by a

[3 H]-palmitate

pulse-labeling

study. Palmitate is rapidly incorporated into palmitoyl
CoA, a substrate for the first enzyme in the de novo
pathway, and the radiolabel in the fatty acid chain is
incorporated into the sphingoid backbone. Further
metabolism in the de novo pathway results in the production
of ceramide whose degree of radiolabeling we assessed by
thin layer chromatography and liquid scintillation
counting. This pulse, rather than equilibrium, approach
results in radiolabeled ceramide that is reflective of de
novo synthesis rather than from constitutive or agonistinduced turn over of sphingomyelin.
The period of pulse-labeling was begun at the same time of
etoposide treatment, and over the course of 12 hours, we
observed a steady increase in ceramide generation up to
two-fold after 12 hours (figure 5). As we observed in
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figure 4 with the mass measurements, corresponding
inhibition in the bcl-2 over-expressing cells was also
observed in the ceramide radiolabeling assay.
That bcl-2 inhibited the ceramide response to etoposide as
assessed by both fumonisin-sensitive mass measurements and
radiolabel analysis provides added confidence that bcl-2 is
functioning as a regulator of the de novo pathway. These
results also differentiate regulation of the de novo and
sphingomyelinases mediated pathways of ceramide generation
as ceramide production by the latter is not inhibited by
bcl-2 (reference 58).
Bcl-2 is a membrane protein located primarily in the
mitochondria. It is an established regulator of apoptosis
and is thought to mediate its inhibitory effects
predominantly through regulating mitochondria events. In
this regard, it prevents the release of cytochrome c from
the mitochondria, subsequent apoptosome formation, and the
activation of executioner caspases. Because we observed
inhibition of de novo ceramidesynthesis in bcl-2
overexpressing cells and because bcl-2 inhibits activation
of both caspase-9 and downstream executioner caspases, we
hypothesized that caspases might be involved in upregulating de novo synthesis.
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To test our hypothesis, we treated Molt-4 cells with
etoposide +/- varying doses of the pancaspase inhibitor,
zVAD.

zVAD inhibited both mass ceramide accumulation

(figure 7) and radiolabeled ceramide accumulation (figure

!)

in etoposide-treated vector control cells.

Correspondingly, the diminished increase of ceramide mass
observed in the Molt-4 bcl-2-transfected cells was not
affected by zVAD (£igure 9).
These results allow us to draw several conclusions. First,
they further implicate the mitochondria as a coordinating
center for stress response. In this case, the DNA damage
induced by etoposide is sensed in an unknown manner by the
mitochondria leading to apoptotic signaling events. In
instances were bcl-2 is upregulated, it is unclear if the
mitochondria still sense the damage or if the damage is
sensed but unable to be acted upon due to the presence of
bcl-2. Second, the results demonstrate the necessity of
caspase activation in de novo ceramide synthesis.
Identification of the caspase(s) involved in this role
awaits further study and will be assessed using caspase
isozyme-specific inhibitors. This is crucial because there
is a growing body of evidence indicating that pan-caspase
inhibitors like z-VAD-fmk,

z-YVAD-frnk, and Z-DEVD-fmk

inhibit other cysteine proteases like cathepsins
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B,H,L,S,K,F,V,X and C (reference 80). Some of these
cysteine proteases especially cathepsin B are involved in
the apoptotic process (references 81-84) which forces us to
take data from pan caspase inhibitors with caution and
emphasizes the importance of future caspase isozymespecific inhibitor .Third, the results open to discussion
the role of de novo ceramide in etoposide-signaling.
Ceramide has been shown in many instances to act further
upstream in stress signaling and coordinating stress
responses. The fact that we observe ceramide generation in
a distal site (on par with the activation of executioner
caspases) in the dogmatic apoptosis cascade might suggest
that it is acting in more of an executioner phase. Fourth
and finally, although we know from prior work that

serin~

palmitoyltransferase activation in this system drives de
novo ceramide generation, we do not know if caspase
activation is necessary for its activation or if it is
necessary for progression through the de novo pathway
downstream of serine palmitoyltransferase.
In conclusion, these results have identified a novel role
for Bcl-2 in inhibiting apoptotic responses and have
identified caspases as regulators of de novo ceramide
synthesis.
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Figure

~egends

Figure 1.Ceramide: demonstrating the resemblances and
differences among the three molecules: Ceramide,
dihydroceramide and diacylglycerol (DAG) . DAG and
ceramide have opposing cellular functions and
dihydroceramide is an inert molecule.
Figure 2. The de novo pathway
Figure 3. Fumonisins: there are significant similarities
between fumonisins and sphingoid bases and they act as
competitive inhibitors of dihydroceramide synthase.
Figure 4. Effects of

Bc~-2

on ceramide production:' Molt-4

cells transfected with Bcl-2 (solid and open circles)
or control vector (solid and open squares) were
treated with 10

etoposide (solid symbols) or vehicle

control (open symbols) for 0-12 hours. At the
indicated time points, the cells were harvested, and
ceramide mass was quantified using diglyceride kinase
assay and normalized to lipid phosphate. The open
circles or squares are for control BCL-2 or vector
cells, respectively.
Figure 5. Effects of

Bc~-2

oncogene on de novo ceramide

production after etoposide treatment: Molt-4 leukemia
cells transfected with Bcl-2 oncogene (solid circles)
or control vector (open squares) were treated with
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10

etoposide and [3 H]-palmitate (1_Ci/ml) for 0-12

hours. At the indicated time interval, cells were
harvested and [3 H]-ceramide quantified. Results
represent the fold increase in ceramide at each point
in comparison to time-matched control.
Figure 6. Sphingomyelinase inhibition using GW 554869a:
Molt-4 cells transfected with Bcl-2 (scored bars) or
control vector (solid bars) were treated with 10
etoposide for 12

hour~.

Concurrent with the addition

of etoposide, GW 554869a using different
concentrations was added. At hour 12, the cells were
harvested and ceramide mass was quantified using DGK
assay. The results were normalized to lipid phosphate.
Figure 7. Effect of caspase inhibition on etoposideinduced ceramide: Molt-4 cells transfected with

control vector were treated in a dose-dependent manner
with the pancaspase inhibitor N-benzyloxycarbonyl-valala-asp-fluromethylketone (z-VAD) for 30 minutes.
Then, 10

etoposide was added and cells incubated for

12 hours before harvesting. Mass ceramide was
quantified using DGK assay and normalized to lipid
phosphate.
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Figure 8. Effect of caspase inhibition on Etoposideinduced de novo ceramide: Molt-4 cells transfected

with control vector were treated in a dose dependant
manner with z-VAD for 30 minutes. Then, 10 __ etoposide
and [3 H]-palmitate (1 Ci/ml) were added simultaneously
for 12 hours. At the end of 12 hours cells were
harvested and [3 H]-ceramide quantified.
Figure 9. Effect of Caspase inhibition on eoposideinduced ceramide in Bc1-2 ce11s: Molt-4 cells

transfected with Bcl-2 oncogene were treated in a
dose-dependent manner with z-VAD for 30 minutes. Then,
10 __ etoposide was added and cells incubated for 12
hours before harvesting. Mass ceramide was quantified
using DGK assay and normalized to lipid phosphate.
Figure 10.

T~e

course for the induction of de novo

Synthesis by etoposide: Molt-4 cells were treated for

0-6 hours with 10

~M

etoposide in the presence (solid

square) or absence (open square) of 50

4S

~M

fumonisin.
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